Loading
A phase 3 trial of Bevacizumab in glioma & glioblastoma and brain and spinal cord tumours, run by NaviFUS Corporation, now recruiting.
A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients is a phase 3 interventional study registered as NCT06496971 by NaviFUS Corporation, with 32 participants planned, started 2024-11-08 and due to reach its primary completion in 2026-12-31. Interventions recorded: Bevacizumab, Microbubble and Low-Intensity Focused Ultrasound.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Glioma & glioblastoma, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Glioma & glioblastoma, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.
Shares Bevacizumab, Glioma & glioblastoma and the tag pipeline.
Shares Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies and the tag pipeline.